Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I think the tech is great and as you say could change the world.
Avacta spun out is 2006 to do just that.
soon....
Some good points alextak and up2myneck
"As previous we know a home use LFT is now accepted to be as good as an x-ray, and in the very near future LFTs with electronic signatures will be accepted instead of doctors notes for example common flu and exhaustion as well as Covid-19.
They will also be able to prove a claimant is not actually ill at all, or the illness is self inflicted example alcoholism and drug use."
No joke this time:
My partner’s relative is an epidemiologist working in Whitehall
He said very similar things about future diagnostic methods and expansions as you did.
Next time I will speak to him personally to further clarify his thoughts as it was my partner who spoke with him :/
EGTP - thank you for your two part post, giving a well rounded overview of Avacta and its possibilities going forward.
I share your medium and long term optimism. The opportunities arising from the IP it owns are enormous, and very varied . The potential is simply enormous.
Like many others I sincerely wish the current issue with the LFT had not arisen - but it has, and I believe that disclosing the shortcomings of the test (a defect probably shared by most if not all other tests) was the right thing to do. Painful (very) in the short term , but nonetheless the right course to adopt. It will help to sustain Avacta’s reputation for honesty and professionalism, and this will serve it well eg when the therapeutics come to market.
The very significant funds lost to date on LFT sales will be seen within about 2-3 years as small beer compared with the revenues likely to flow from the therapeutics arm - assuming that the AVA6000 etc trials are as successful as we all hope - and have some reason to expect - they will be.
Short term pain, long term gain - all being well. Nothing at all is guaranteed, of course, and the risk of failure certainly exists, but there are grounds for real optimism, I believe.
I’ve been invested since 2013 and increased my investment when the Covid test prospects appeared - but my real reason for being here at all remains as before - ie the prospect of enhanced treatments for cancer. I will be holding until the likes of AVA6000 etc come to fruition - or, we get taken over, whichever comes first.
Nice post. Just to clarify, AVA6000 does not involve Affimers. Precision is a different platform.
Excellent post EGTP
Part 2
Mass testing for all purposes including sewage monitoring (Deepverge using Affimers) is the direction the brave new world is heading, and nothing will stop this revolution happening. Not only will the best most accurate LFT’s save time, lives and infections spreading, they will also be able to cut down truancy and instantly endorse sick pay and right to time off work - this is what Medusa-19 have their focus on, and this is why they’ve been so patient for so long.
I was first attracted to this stock in April 2020 simply because of it’s AffiDX solution, but having read about Affimers and understood their simply brilliant performance and adaptability to bind to just about every known disease and virus particle within the body – I now understand the bigger picture
If your in just for the AffiDX fine - the world will need the best LFT tests to detect Covid for the next 5 to 10 years. Yes early boats have been missed, but 1000’s more await (just like Google finally championed over Altavista and Ask Jeeves) but do understand it’s just a sideline, which I believe will become one of many multi £billion diagnostic arms of Avacta, along with the precision platform deals, Affimer Sales, Partnerships and it’s own products namely AVA6000 / 3996.
Avacta’s deal with LG Chem is worth more than double the current Market cap alone, the milestones recently achieved with Point Bio Pharma seem to be totally ignored, and the fact Avacta's market cap has dropped by £100 million since the Affidx update somehow suggests the market now believes £100 million of LFT sales profit has been lost.
As far as the Uk Govs attitude to Avacta is concerned - well the political landscape will be changing shortly too. I was reliably informed 2 weeks ago that the Government were tripling the supply of free lateral flow tests in January and February to 300 million per month. They also intended to distribute 600,000 packs of 7 tests on gov.uk directly to homes every day, this is an overview of the UK market alone.
For me Avacta is an investment, not a day trade or short hold, so don’t buy £1 of this stock until you properly understand Avacta and it’s Affimers
GLA and DYOR
Part 1
Just to cover some of my previous - yes regrettably for most holders, I still 100% agree with the decision to temporarily pause AffiDX, in order to revise and quickly relaunch an improved version. This just had to be done, and the greater good will be soon be clear, when AVA6000 feedback is released, and the trials in the US commence.
To venture a little further into AVA6000, try not to blind yourselves, and others by the science. It’s simple, Avacta have found a way for its Affimers to deliver precision chemotherapy using standard doxorubicin delivery at up to 10 times normal strength, with virtually zero side effects. This is an absolutely stunning development, and means serious, and terminally ill cancer sufferers now have the option of gambling virtually nothing, for the chance of a normal healthy life.
And the best part - this isn’t a new novel treatment that needs years and years of trials, it’s just a modification of how the current treatments are being delivered, proof of concept is already in action ! and the UK trial results are imminent, if this news is as good as what one would expect the FDA to require to allow Avacta into the US - how much is this single delivery method for just one treatment alone worth to the world ?
Yes it’s true the market can’t see the wood for the trees, so I have to agree (in part) with some of the regular doomsday mob because they do have a point. And because the current market value is now so low, outsiders simply don’t believe its possible our company could have such good Technology. Its pure Psychology, if we were a £2 Billion market cap investors would invest seriously, so as a result the market may choose to even ignore the success of AVA6000 trials for now, simply because it doesn’t understand Avacta. And because it’s so obsessed with the SARS Cov Antigen test it can’t even comprehend the purpose and Benefit of Medusa-19 - which takes me back to another previous post
‘Who are Medusa-19 and what use are they to Avacta’
Because of coronavirus, the world is now changing forever, which makes me pretty sure Hughes and Karmani couldn’t give a toss that their current avacta holding is only worth around ¼ of what it was around 6 months ago. Hughes and Kamani are totally focused on exploiting AffiDX via Medusa-19 to fit it into the new emerging world, and they know by doing so, they will open more doors for Avacta
As previous we know a home use LFT is now accepted to be as good as an x-ray, and in the very near future LFT’s with electronic signatures will be accepted instead of doctors notes for example common flu and exhaustion as well as Covid-19.
They will also be able to prove a claimant is not actually ill at all, or the illness is self inflicted example alcoholism and drug use.
spot on CO!
Great post EGTP.
Some key points for me:
- Every time the crest of a wave of covid breaks (as omicron might be doing in parts of the UK), people start clamouring that it’s all over for the pandemic and we’re all going back to normal tomorrow. Experience suggests this is not the case.
- Future variants will come.
- Every winter season will see a fresh wave of these and existing variants, especially as immunity wanes over time.
- There are always other countries still on the exponential rise leg of their covid journey.
- Governments are still buying, but I think in the longer term the private market will be the one that sticks.
- People in many countries have gotten familiar with using lateral flow tests, and take them before going places or seeing people.
- People (and employers) are willing to pay for lateral flow tests in countries that don’t offer them for free, and even in some that do.
Patience required, but I am sure the market and the chance of success on this in the mid to long term for Avacta is better than most currently think.
Nice posts EGTP and Poirot,
It would make very little sense to only focus on covid-19 and I am sure there will be plenty of R&D development in the background for many other test targets. The general infrastructure for the testing market has changed and we find ourselves in the position where covid testing is here to stay for years to come. As I mentioned in another post, as there is a corpus of individuals who refuse to vaccinate, (irrespective of whether their reasoning is good or bad), or due to ill health; there will remain a reservoir in which the virus will mutate and new Variants of Concern will appear. See my post on Covid a long term thread [1] - I will also link back to this thread. This will make testing a part of our society and will continue to pave the way for multiple pivotal movements within the diagnostics arena. As Poirot has said, Richard Hughes is an exceptionally good deal maker with a fantastic record.
GLA
1. https://www.lse.co.uk/ShareChat.asp?ShareTicker=AVCT&share=Avacta&thread=A2153B7A-D8AD-463A-9D74-B69683070B95
Great post EGTP and mirrors my thoughts on why Richard Hughes especially founded Medusa19. The guy is one of the best deal makers around, and im led to believe very good at spotting future trends. His investment record speaks for itself and he’s holds almost 3% of Avacta for good reason.
On the other side of the fence, Avacta have identified rapid POC diagnostics as a key area of focus for the Wetherby business unit. Medusa19 will be a key partner in marketing AffiDX tests to a global audience, effectively becoming the retail arm of Avacta, allowing Al and his team to focus on the science - a great move by Avacta imo.
I think I said it before Xmas, but the M19/Avacta goes way beyond Covid. We’ve had a minor set back, but I still expect this to be a very rewarding tie up for Avacta shareholders.
Couldn’t agree more EGTP, hence why I think M19 is likely to have a strong future regardless of Covid, particularly given its links with AVCT and affimer tech, and why I’ve had a small punt in LSAI.
No problems oddmoney - but Please don’t increase your investment Because if my commentary !
I’m just the average nobody that believes he can see into the future
Have good weekend all !
DYOR
Thank you EGTP, the statement "home self testing / diagnosis is more accurate than going to see your GP" did have the exact effect that you expected. I need to up my investment :)
Further to my last, I would also like to invite the de-rampers and doomsters, plus beg forgiveness in advance (to some genuine holders) to open their eyes and expand their minds even further to understand what has happened, and where things are now guaranteed to now go in the future
Back in 2001 A guy called Richard Colvin Reid inadvertently created a multi billion dollar Industry trying to blow up a plane. As a result you now cannot fly anywhere in the modern world without you, and your baggage’s been X-ray scanned.
Fast forward to 2022 it has now been accepted that home self testing / diagnosis is more accurate than going to see your GP, and it is at least as reliably accurate as going to hospital for a PCR test - which is in effect an x-ray scan.
The reason the avacta sars cov antigen test has been branded ‘AffiDX’ is because more tests are currently being developed using the cutting edge affimer technology https://en.wikipedia.org/wiki/Affimer to produce Cortisol, Sepsis, Vitamin D, Cholesterol ect (maybe even a test to detect delusion and stupidity for some ;-0)
As a result of Coronavirus Home Self testing / diagnosis will become a multi £trillion (never mind billion) industry within the next 5 to 10 years, anyone that doubts this needs to ask themselves this question.
How much money, time and valuable lives could be saved if Doctors, GP’s, Nurses and Hospital resources could do just what they used to do 50 years ago – rather than spending 90% of their current time confirming the obvious, as well as endless paperwork and phone calls – when this could have already be done and confirmed by the patient ?
I haven’t spoke with Kamani or Hughes personally, but can absolutely guarrantee they’ve no interest in just recovering to breakeven their £22 plus million investment in https://www.medusa19.com/ from the production / sale to the home user of maybe 50 million Affidx or ‘Meduflow’ tests as a result of their partnership / profit share with Avacta.
No sir - their vision is way beyond that, and from being major share holders in Avacta they have good reason to believe this, knowing full well how good Affimers and the precision technology they create are, to perfect these future home self tests in the pipeline
Mark my words the future of the world, and self diagnosis for Covid-19 is considerably bigger than the Affidx Antigen test produced by Avacta, which is in itself only a sideline (maybe 5%) of what Avacta Life Sciences is all about.
Hopefully the penny has now dropped for some !
GLA and DYOR